Enhancing the Acceptability of Psychological Treatments for Obsessive-compulsive Disorder
1 other identifier
interventional
100
1 country
1
Brief Summary
Effective treatments for obsessive-compulsive disorder (OCD) usually emphasize a behavioural approach called Exposure and Response Prevention (ERP). In this treatment, patients are encouraged to face their fears repeatedly and for extended periods of time, with the help and support of a caring therapist. Although this is an approach that has been shown to work, many patients find the treatment to be difficult; some even refuse the treatment, or drop out before improvements are seen. The investigators have been working to develop an alternate approach which is just as effective as ERP, but which the investigators think will be much more acceptable to those who seek help for their OCD. This study will compare the traditional behavioural approach, with the newer cognitively-based approach. The investigators expect that the two treatments will both reduce the symptoms and distress of people with OCD, but that this newer cognitive therapy will have fewer people who refuse or drop out of the treatment, and will be rated as more acceptable. This research will have important implications not only for those struggling with OCD, but also for other anxiety-related problems where behavioural approaches are typically recommended, including posttraumatic stress disorder, social anxiety disorder, and other problems.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2019
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 20, 2018
CompletedFirst Posted
Study publicly available on registry
September 7, 2018
CompletedStudy Start
First participant enrolled
January 26, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2024
CompletedFebruary 7, 2024
February 1, 2024
5.4 years
August 20, 2018
February 5, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Incidents of participants that drop-out of treatment
The investigators will keep a record of the number of participants that drop-out of treatment.
Week 2, through treatment completion.
Incidents of participants that refuse treatment
The investigators will keep a record of the number of participants that refuse the treatment.
Baseline, up to week two.
Treatment and Acceptability Adherence Scale (TAAS; Milosevic, Levy, Alcolado & Radomsky, 2015)
The TAAS is a validated 10-item self-report questionnaire designed to assess treatment acceptability and anticipated adherence in response to a given treatment for anxiety and related problems. It is intended to be administered to potential treatment recipients after they have received information about the treatment. Items are rated on a 7-point Likert-type scale (1 Disagree strongly; 7 Agree strongly) to assess the degree to which participants agree with a variety of statements about a given treatment. Total scores are obtained by summing across all items after negatively worded items (3, 4, 5, 7, 8 and 10) have been reverse-scored. Scores may range from 10 to 70, with higher scores indicating greater acceptability of treatment and greater anticipated ability to adhere to it.
Through study completion (week 3; week 6; one week post therapy; 6 month follow-up; 12 month follow-up).
Secondary Outcomes (3)
The Vancouver Obsessional Compulsive Inventory (VOCI; Thordarson, Radomsky, Rachman, et al., 2004)
Through study completion (Baseline; week 6; one week post therapy; 6 month follow-up; 12 month follow-up).
Anxiety Disorders Interview Schedule for DSM-5 (ADIS-5; Brown & Barlow, 2014)
Through study completion (Baseline; one week post therapy; 6 month follow-up; 12 month follow-up).
The Yale-Brown Obsessive Compulsive Scale (YBOCS; Goodman, Price, Rasmussen, et al., 1989)
Through study completion (Baseline; week 6; one week post therapy; 6 month follow-up; 12 month follow-up).
Study Arms (2)
Cognitive Therapy
EXPERIMENTALA modularized, cognitive-behavioural therapy intervention that incorporates evidence gathering and behavioural experiments. Our CT protocols rely heavily on behavioural experiments which are typically targeted and brief exercises designed to permit clients/patients to gather disconfirmatory evidence about their beliefs.
Behavioural Therapy
ACTIVE COMPARATORMethod of behavioral therapy and form of exposure and response prevention therapy in which individuals confront their fears and discontinue their escape response. Exposures in this protocol are prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
Interventions
Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Twelve treatment sessions include components to foster cognitive (i.e. thinking) and behavioural changes.
Exposure therapy in which individuals confront their fears and discontinue their escape response. Twelve treatment sessions implementing exposure which is prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
Eligibility Criteria
You may qualify if:
- Diagnosis of OCD
- Ability to read, write, and communicate in English
You may not qualify if:
- Psychosis
- Diagnosis of bipolar disorder (I or II)
- Current suicidal ideation/intent
- Current substance abuse
- If participants are on medication they must be on a stable dose (i.e. have maintained a consistent dose for at least three months) and agree not to change their medication regimen for the duration of the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Concordia University, Montreallead
- Université de Montréalcollaborator
- McGill Universitycollaborator
- University of British Columbiacollaborator
- University College London Hospitalscollaborator
Study Sites (1)
Concordia University
Montreal, Quebec, H4B1R6, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Adam S Radomsky, PhD
Concordia University, Montreal
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- Intervention assessors will not know which participants have been assigned to the different interventions.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
August 20, 2018
First Posted
September 7, 2018
Study Start
January 26, 2019
Primary Completion
June 1, 2024
Study Completion
June 30, 2024
Last Updated
February 7, 2024
Record last verified: 2024-02
Data Sharing
- IPD Sharing
- Will not share